Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin

European Journal of Pharmacology

Volumn 565, Issue 1-3, 2007, Pages 26-36

  Holt, Sandra ^a   Paylor, Ben ^a   Boldrup, Linda ^a   Alajakku, Kirsi ^a   Vandevoorde, Séverine ^a   Sundström, Anna ^a   Cocco, Maria Teresa ^b   Onnis, Valentina ^b   Fowler, Christopher J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Anandamide; Cannabinoid receptor; Cyclooxygenase; Fatty acid amide hydrolase; Nonsteroidal anti inflammatory drug

Indexed keywords

6 METHYL PYRIDIN 2 YL IBUPROFEN DERIVATIVE; ACYLGLYCEROL LIPASE; AMIDASE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOCANNABINOID; FATTY ACID AMIDASE; IBUPROFEN; IBUPROFEN DERIVATIVE; INDOMETACIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN MEMBRANE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOMA CELL; HYDROLYSIS; IC 50; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN BINDING; RAT;

AMIDOHYDROLASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACIDS; BRAIN; CYCLOOXYGENASE INHIBITORS; ENDOCANNABINOIDS; ENZYME INHIBITORS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; IBUPROFEN; INDOMETHACIN; MICE; MICE, INBRED BALB C; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

EID: 34249091033     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.02.051     Document Type: Article

References (43)

1. Andersson S.E., Lexmüller K., Johansson A., and Ekström G.M. Tissue and intracellular pH in normal periarticular soft tissue and during different phases of antigen induced arthritis in the rat. J. Rheumatol. 26 (1999) 2018-2024
2. Ates M., Hamza M., Seidel K., Kotalla C.E., Ledent C., and Gühring H. Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. Eur. J. Neurosci. 17 (2003) 597-604
3. Bisogno T., Maurelli S., Melck D., De Petrocellis L., and Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272 (1997) 3315-3323
4. Boldrup L., Wilson S.J., Barbier A.J., and Fowler C.J. A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J. Biochem. Biophys. Methods 60 (2004) 171-177
5. Bouaboula M., Hilairet S., Marchand F., Fajas L., Le Fur G., and Casellas P. Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol. 517 (2005) 174-181
6. Brengdahl J., and Fowler C.J. A novel assay for monoacylglycerol hydrolysis suitable for high-throughput screening. Anal. Biochem. 359 (2006) 40-44
7. Cocco M.T., Congiu C., Onnis V., Morelli M., and Cauli O. Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. Eur. J. Med. Chem. 38 (2003) 513-518
8. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., and Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 9371-9376
9. Eisenthal R., and Cornish-Bowden A. The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters. Biochem. J. 139 (1974) 715-720
10. Fowler C.J., Tiger G., and Stenstrom A. Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship. J. Pharmacol. Exp. Ther. 283 (1997) 729-734
11. Fowler C.J., Janson U., Johnson R.M., Wahlström G., Stenström A., Norström K., and Tiger G. Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac and flurbiprofen. Arch. Biochem. Biophys. 362 (1999) 191-196
12. Fowler C.J., Holt S., and Tiger G. Acidic nonsteroidal anti-inflammatory drugs inhibit rat brain fatty acid amide hydrolase in a pH-dependent manner. J. Enz. Inhib. Med. Chem. 18 (2003) 55-58
13. Gallant M., Dufresne C., Gareau Y., Guay D., Leblanc Y., Prasit P., Rochette C., Sawyer N., Slipetz D.M., Tremblay N., Metters K.M., and Labelle M. New class of potent ligands for the human peripheral cannabinoid receptor. Bioorganic Med. Chem. Letters 6 (1996) 2263-2268
14. Gühring H., Hamza M., Sergejeva M., Ates M., Kotalla C.E., Ledent C., and Brune K. A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur. J. Pharmacol. 454 (2002) 153-163
15. Guindon J., De Léan A., and Beaulieu P. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 121 (2006) 85-93
16. Guindon J., LoVerme J., De Léan A., Piomelli D., and Beaulieu P. Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides?. Eur. J. Pharmacol. 550 (2006) 68-77
17. Häbler C. Über den K- und Ca-gehalt von eiter und exsudaten und seine beziehungen zum entzündungsschmerz. Klin. Wochenschr. 8 (1929) 1569-1572
18. Holt S., and Fowler C.J. Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pH. Naunyn-Schmiedeberg's Arch. Pharmacol. 367 (2003) 237-244
19. Holt S., Nilsson J., Omeir R., Tiger G., and Fowler C.J. Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen. Br. J. Pharmacol. 133 (2001) 513-520
20. Holt S., Comelli F., Costa B., and Fowler C.J. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br. J. Pharmacol. 146 (2005) 467-476
21. Jayamanne A., Greenwood R., Mitchell V.A., Aslan S., Piomelli D., and Vaughan C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 147 (2006) 281-288
22. Kalgutar A.S., Crews B.C., Rowlinson S.W., Marnett A.B., Kozak K.R., Remmel R.P., and Marnett L.J. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 925-930
23. Kalgutar A.S., Marnett A.B., Crews B.C., Remmel R.P., and Marnett L.J. Ester and amide derivatives of the nonsteroidal anti-inflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 43 (2000) 2860-2870
24. Kavvada K.M., Murray J.G., Moore V.A., Coombes A.G.A., and Hanson P.J. High permeability of the anionic form restrics accumulation of indomethacin by cultured gastric surface epithelial cells exposed to low apical pH. Eur. J. Pharmacol. 549 (2006) 41-49
25. Kozak K.R., and Marnett L.J. Oxidative metabolism of endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids 66 (2002) 211-220
26. Lichtman A.H., Shelton C.C., Advani T., and Cravatt B.F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109 (2004) 319-327
27. Lo Verme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A., and Piomelli D. The nuclear receptor PPAR-α mediates the antiinflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67 (2005) 15-19
28. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., and Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 11693-11697
29. 2 receptor: signalling via cAMP and inositol phosphates. FEBS Lett. 536 (2003) 157-160
30. Paria B.C., Deutsch D.D., and Dey S.K. The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period. Mol. Reprod. Dev. 45 (1996) 183-192
31. Paylor B., Holt S., and Fowler C.J. The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH. Pharmacol. Res. 54 (2006) 481-485 Erratum published in Pharmacol. Res. 55, 80 (2007)
32. Rakhshan F., Day T.A., Blakely R.D., and Barker E.L. Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J. Pharmacol. Exp. Ther. 292 (2000) 960-967
33. Riendeau D., Charleson S., Cromlish W., Mancini J.A., Wong E., and Guay J. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can. J. Physiol. Pharm. 75 (1997) 1088-1095
34. Sandberg A., and Fowler C.J. Measurement of saturable and non-saturable components of anandamide uptake into P19 embryonic carcinoma cells in the presence of fatty acid-free bovine serum albumin. Chem. Phys. Lipids 134 (2005) 131-139
35. Schmid P.C., Zuzarte-Augustin M.L., and Schmid H.H.O. Properties of rat liver N-acylethanolamine amidohydrolase. J. Biol. Chem. 260 (1985) 14145-14149
36. Singh Tahim A., Sántha P., and Nagy I. Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons. Neuroscience 136 (2005) 539-548
37. Sofia R.D., Vassar H.B., and Knobloch L.C. Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats. Psychopharmacologia 40 (1975) 285-295
38. Thors, L., Alajakku, K., Fowler, C.J., in press. The "specific" tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide. Implications for anandamide uptake. Br. J. Pharmacol.
39. Tiger G., Stenström A., and Fowler C.J. Pharmacological properties of rat brain fatty acid amidohydrolase in different subcellular fractions using palmitoylethanolamide as substrate. Biochem. Pharmacol. 59 (2000) 647-653
40. Ueda N., Yamanaka K., and Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J. Biol. Chem. 276 (2001) 35552-35557
41. Ulugöl A., Özyigit F., Yeşilyurt Ö., and Dogrul A. The additive antinociceptive interaction between WIN55,212-2, a cannabinoid agonist, and ketorolac. Anesth. Analg. 102 (2006) 443-447
42. Vandevoorde S., Jonsson K.-O., Fowler C.J., and Lambert D.M. Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide. J. Med. Chem. 46 (2003) 1440-1448
43. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H.-h., Sørgård M., Di Marzo V., Julius D., and Högestätt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (1999) 452-457